Quanterix (QTRX) Q3 2026 earnings review
Quanterix sales rise from last quarter, but cash burn triples
Quanterix, a maker of ultra-sensitive blood and tissue protein tests, grew sales from the second quarter while burning more cash. Comparable revenue fell 9% from a year ago — a smaller drop than the 23% decline in the first half — as chief executive Everett Cunningham reorganized the sales force. However, third-quarter cash burn nearly tripled from the second quarter to $16 million, so management cut its year-end cash target by $10 million and trimmed the top end of its revenue outlook.
| Comparable revenue (including Akoya a year ago) | $35.0M -9% from a year ago (+6.3% from Q2) |
|---|---|
| Reported revenue | -13% from a year ago (laps July 2025 Akoya deal) |
| Cash and securities on hand | $80.7M burned $16.2M in Q3 |
| Full-year outlook | Cash cut $10M revenue top end trimmed $2M to $142–146M |
⚖️ Verdict: 🔴 Bearish
The story got worse because cash preservation — a bright spot in the second quarter — gave way as operating expenses climbed back above 100% of revenue. The company used nearly its entire second-half cash allowance in a single quarter and lowered its year-end cash plan for the second time in three months. On the brighter side, strong US chemical sales and new Florida Medicaid coverage for its Alzheimer's blood test showed that commercial execution is improving.
The question now is whether the reorganized sales team can lift revenue fast enough in 2027 to cover a $140 million yearly operating expense base without raising capital. Either higher instrument and test volumes close the gap, or the cost base remains too large for a business of this size. Fourth-quarter cash burn and the initial 2027 outlook will tell.
🐂 Bull Case
US Consumables Slowed the Comparable Sales Drop
Quanterix sells ultra-sensitive blood-testing machines called Simoa and tissue-analysis tools from Akoya Biosciences, which it bought in July 2025. Chief executive Everett Cunningham reorganized the sales team by product line last quarter to fix commercial execution. "We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness," Cunningham said.
Because the Akoya deal closed a year ago, reported revenue swung from 34.4% growth in the second quarter to a 13.1% drop in the third. On a comparable basis that includes Akoya in both years and removes a canceled contract, sales fell 9%, a smaller drop than the 23% decline in the first half. Near-record tissue chemical sales and mid-teens sequential growth in US academic labs drove the improvement.
What to watch: fourth-quarter revenue against the $39.7 million middle of the full-year outlook. Reaching that level would bring the comparable year-over-year decline down to 1%.
Alzheimer's Blood Test Gained Florida Medicaid Coverage
The biomarker group is building a clinical testing business around LucentAD Complete, its blood test that measures five proteins to help diagnose Alzheimer's disease. In September the company hired its first chief medical officer, Yuri Fesko, to lead clinical and regulatory work alongside a dedicated diagnostics sales team.
Starting November 1, Florida Medicaid covers qualifying blood biomarker tests, including LucentAD Complete, at $484 per test for four million residents and state employees. The company also added regional clinical lab partners in New York and Mississippi, won regulatory approval for four neurology tests in China with partner Innovita, and doubled LucentAD test volume from the second quarter.
What to watch: dollar revenue from diagnostics partners on the conference call or in the quarterly filing. Management previously targeted more than $10 million for 2026 after booking $4.5 million in the first half, so the second half needs at least $5.5 million.
🐻 Bear Case
Cash Burn Rose and Cut the Year-End Target
Quanterix finished integrating Akoya in the second quarter and captured $85 million in yearly cost savings, which kept second-quarter cash burn to $5.7 million. Last quarter management lowered its 2026 year-end cash target from $100 million to $80 million and pushed its cash-flow breakeven goal out to 2027.
In the third quarter, the company burned through $16.2 million of cash, nearly all of the $16.9 million that the prior $80 million target allowed for the entire second half by our math. Selling, general and administrative expenses fell 13.2 percentage points of revenue from a year ago as integration fees ended. However, operating expenses excluding one-offs rose 11.6% from the second quarter to $35.4 million, or 101.3% of revenue, as the company hired commercial leaders.
- Third-quarter cash burn: $16.2 million, up from $5.7 million in the second quarter
- Operating expenses excluding one-offs: $35.4 million, up $3.7 million from the second quarter
- Year-end 2026 cash outlook: cut to about $70 million, implying $10.7 million of fourth-quarter burn by our math
What to watch: fourth-quarter operating expenses excluding one-offs. Even at the $39.7 million revenue implied by the outlook and a 49.4% gross margin, quarterly cash operating costs above $30 million will keep the company burning cash into 2027.
Trimmed Outlook Still Needs a Steep Q4 Step-Up
Cunningham brought in a new chief commercial officer in mid-August and said "reorganizing our teams and adding experienced leadership and discipline, should accelerate our execution in the fourth quarter and beyond." At the same time, the company announced it is "narrowing its expectations for total revenues to $142-146 million" from $142–148 million, trimming the middle of the range by $1 million.
By our math, the new $144 million midpoint leaves $39.7 million for the fourth quarter, which requires a 13.5% jump from the third quarter while a new sales team is still settling in. Meanwhile, total deferred revenue — cash customers have paid upfront for services and warranties — slipped another 1.9% from the second quarter to $17.1 million, giving the company less contracted revenue to start the fourth quarter.
What to watch: total deferred revenue at year-end. A fourth straight quarterly drop would show that upfront service and warranty contracts are still shrinking going into 2027.
European Pharma Weakness Held Back Lab Services
Through its Accelerator Laboratory, Quanterix runs custom biomarker studies for drugmakers. That service business has shrunk since early 2025 as pharmaceutical customers ordered smaller projects.
In the third quarter, total service and other revenue fell 33.3% from a year ago to $9.4 million, and rose just 3.8% from the second quarter. Accelerator Lab bookings grew by a mid-teens percentage from the second quarter — the second straight quarterly rise — and the lab added 21 Simoa drug trial projects to reach 304 this year. Yet Accelerator revenue stayed flat from the second quarter at $3.0 million by our math, as weaker demand from European drugmakers and research organizations offset US gains.
What to watch: fourth-quarter service and other revenue. If the two quarters of higher Accelerator bookings do not lift service revenue above $10 million, drugmakers are taking longer to turn orders into paid lab work.
Risks this quarter didn't answer
Three standing concerns from prior quarters received no new numbers or resolution in the third-quarter release and presentation.
- Diagnostics revenue in dollars: the release noted that LucentAD test volume doubled, but did not report dollar revenue from diagnostics partners ($1.6 million in the second quarter).
- FDA clearance for LucentAD Complete: the company submitted its application in January and reported active dialogue with the agency, with a decision still pending.
- Intangible asset value: $102.4 million of acquired intangible assets remain on the balance sheet after last quarter's $26.9 million goodwill write-off, and the quarterly filing will update impairment tests.
👓 Other Themes
New Tissue Panels Ship Early Next Year
In September Quanterix launched three products for its spatial biology business, which maps proteins inside tissue samples. The PhenoCode 2.0 kit is on sale now, "enabling researchers to barcode virtually any antibody in applications spanning immuno-oncology, neuroscience and other areas." Two new oncology test panels — one for tumor immune environments and one for targeted cancer drugs — will start shipping in early 2027, while the Accelerator Lab now takes custom panel orders.
💲 Other KPIs
Uncollected customer bills rose 21.7% ($4.9 million) from the second quarter, more than three times the 6.3% sequential increase in revenue. That buildup tied up cash during the third quarter after collections had helped lower cash burn in the first half.
Stock on hand fell 5.8% ($2.8 million) from the second quarter and is down $9.9 million since the end of 2025. Working down the inventory acquired with Akoya generated $9.7 million of operating cash over the first nine months of the year.
The company added 22 net new instruments in the third quarter — 10 Simoa blood analyzers and 12 Spatial tissue imagers, by our math — after adding 50 across the first two quarters of the year. The total installed base of 1,130 Simoa and 1,480 Spatial machines drives recurring chemical sales.
🔮 Guidance
Cut at the top end. The middle of the range moved down $1 million to $144 million, after a $26.5 million cut last quarter from the original $169–174 million plan. By our math, the outlook leaves $39.7 million for the fourth quarter — up 13.5% from the third quarter, and down 9.5% reported (or 1% on a comparable basis) from a year ago.
Unchanged. The full-year target stays at 48–50% after management lowered it from 49–53% last quarter. Through nine months, gross margin excluding one-offs sits at 48.8% (47.4% in the third quarter), which by our math leaves 49.4% for the fourth quarter at the middle of the range as higher sales volume covers fixed factory costs.
Cut. Management lowered its year-end cash target by $10 million, the second cut in two quarters after starting the year at $100 million. With $80.7 million on hand at the end of September, the new plan points to $10.7 million of cash burn in the fourth quarter by our math, down from $16.2 million in the third quarter.
Unchanged. The biomarker group carries no debt after paying off Akoya's loans at the time of the acquisition last year, and plans to finish 2026 with zero borrowings.
❓ Key Questions
What was dollar revenue from diagnostics in Q3?
The presentation stated that LucentAD test volume doubled, but omitted the dollar revenue figure ($1.6 million in Q2 and $2.9 million in Q1). Investors need the dollar amount to see if the company can still beat its $10 million full-year target.
Why did operating expenses excluding one-offs jump $3.7 million?
After the company completed its $85 million Akoya cost-savings program in Q2, operating expenses excluding one-offs rose 11.6% sequentially in Q3 to $35.4 million. Management has not said whether that increase is the new quarterly cost base or includes temporary commercial hiring costs.
Has the FDA asked for more data on LucentAD Complete?
Quanterix submitted its 510(k) application for the five-marker Alzheimer's blood test in January 2026 and previously expected clearance toward the end of this year. The presentation noted active FDA dialogue, leaving the approval timeline open.
What are the dollar bookings behind the Accelerator Lab's rise?
Accelerator bookings grew by a mid-teens percentage sequentially for a second quarter, but lab service revenue stayed flat at $3.0 million by our math. Disclosing dollar backlog and conversion timing would show when those orders turn into revenue.